Cargando…
Correction to: NP213 (Novexatin(®)): A unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10446138/ https://www.ncbi.nlm.nih.gov/pubmed/37611076 http://dx.doi.org/10.1093/mmy/myad088 |
| _version_ | 1785094337041793024 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10446138 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104461382023-08-24 Correction to: NP213 (Novexatin(®)): A unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile Med Mycol Correction Oxford University Press 2023-08-23 /pmc/articles/PMC10446138/ /pubmed/37611076 http://dx.doi.org/10.1093/mmy/myad088 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| spellingShingle | Correction Correction to: NP213 (Novexatin(®)): A unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile |
| title | Correction to: NP213 (Novexatin(®)): A unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile |
| title_full | Correction to: NP213 (Novexatin(®)): A unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile |
| title_fullStr | Correction to: NP213 (Novexatin(®)): A unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile |
| title_full_unstemmed | Correction to: NP213 (Novexatin(®)): A unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile |
| title_short | Correction to: NP213 (Novexatin(®)): A unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile |
| title_sort | correction to: np213 (novexatin(®)): a unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10446138/ https://www.ncbi.nlm.nih.gov/pubmed/37611076 http://dx.doi.org/10.1093/mmy/myad088 |